AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

One reason for not achieving better results in chronic bacteriuria, even after protracted antimicrobial therapy, may be failure to differentiate two patterns of recurrent infections – namely ...

route of administration and duration of antimicrobial therapy. Core members of the team should include a physician and a clinical pharmacist, both with training in infectious diseases with an ...

The development of nanodrugs targeting multidrug-resistant bacteria, while sparing the beneficial constituents of the microbiome, has emerged as a promising approach to combat disease and curb the ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

Jason B. Pieper, DVM, MS, DACVD, talked about pyoderma, including ingredients and formulations, in his lecture at the 2025 ...

In a lecture at VMX, Jason B. Pieper, DVM, MS, DACVD, outlined the next steps in the treatment of pyoderma in dogs when the ...

Nat Clin Pract Gastroenterol Hepatol. 2005;2(4):191-198. As antimicrobial resistance increases with more widespread use of these drugs, newer drugs with less potential for the development of ...